Esperion Therapeutics, Inc. — Director's Dealing 2022

May 27, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Esperion Therapeutics, Inc. (ESPR)
CIK: 0001434868
Period of Report: 2022-05-26

Reporting Person: Fuhrman Alan (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-05-26	Stock Option (right to buy)	$5.51	A	20000	Acquired	2032-05-26	Common Stock (20000.0)	Direct

Footnotes

F1: The awards vest in full on the earlier of (i) May 26, 2023 and (ii) the Issuer's next annual meeting of stockholders following May 26, 2022.